Infliximab in neurosarcoidosis: a systematic review and meta‐analysis
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.51968 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Siwakorn Chaiyanarm und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. Hauptthemen laut MEDLINE: Infliximab, Sarcoidosis, Central Nervous System Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.
Methods
A systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases. The search included studies from their inception to March 2023. We included case‐series studies with at least 10 neurosarcoidosis patients undergoing any treatment type. Studies were also required to report at least one of the following outcomes: response rate, overall survival rate, or relapse rate. This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. A random‐effects model facilitated the analysis of proportional treatment outcomes. Study quality was evaluated using the modified Newcastle–Ottawa quality assessment scale, while a funnel plot helped detect any publication bias.
Results
Seven studies comprising 237 patients with neurosarcoidosis were included in the analysis. Of these patients, 184 (77.6%) received treatment with infliximab. The pooled proportion of patients showing clinical improvement after infliximab treatment was 0.74 (95% CI 0.64–0.84, I 2 = 49.73%). Relapse rates, derived from four studies, stood at 0.38 (95% CI 0.22–0.55, I 2 = 56.92%). Most studies reported successful tapering or cessation of corticosteroid dosage in patients receiving infliximab. Adverse effects were reported in 52 (29.4%) patients, of which 39 out of 54 events (72.2%) were linked to infections.
Interpretation
Infliximab demonstrated potential improvement in clinical outcomes for patients with refractory neurosarcoidosis and showed potential for reducing the dosage of concurrent corticosteroids. However, a degree of relapse was observed, with infections being the primary concern for adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Siriraj Neuroimmunology Center, Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
ORCID-Profile: Jiraporn Jitprapaikulsan, Witsarut Nanthasi
Zitieren
APA
Chaiyanarm, S., Satiraphan, P., Apiraksattaykul, N., Jitprapaikulsan, J., Owattanapanich, W., Rungjirajittranon, T., & Nanthasi, W. (2024). Infliximab in neurosarcoidosis: a systematic review and meta‐analysis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51968
Vancouver
Chaiyanarm S, Satiraphan P, Apiraksattaykul N, Jitprapaikulsan J, Owattanapanich W, Rungjirajittranon T, et al. Infliximab in neurosarcoidosis: a systematic review and meta‐analysis. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.51968
BibTeX
@article{Chaiyanarm2024,
author = {Chaiyanarm, Siwakorn and Satiraphan, Piraya and Apiraksattaykul, Natnasak and Jitprapaikulsan, Jiraporn and Owattanapanich, Weerapat and Rungjirajittranon, Tarinee and Nanthasi, Witsarut},
title = {Infliximab in neurosarcoidosis: a systematic review and meta‐analysis},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.51968}
}
EUVIMED